The drug can be used to treat adults and children over 12 years of age who meet relevant criteria and are at risk of developing severe COVID-19 symptoms, according to protocols developed by the National Scientific Committee.
Studies have shown that the drug prevents the progression of the disease to severe cases or death in more than 85 percent of early treatment cases, and it can treat all mutated forms known to date.
The Ministry of Health and Community Protection has approved the new drug sotrofimab, from the “GlaxoSmithKline” company, after completing the national evaluation procedures, and after it was approved by the US Food and Drug Administration and granted an emergency use license.
The Department of Health Abu Dhabi signed a cooperation agreement with Rafid Company to ensure the early delivery of the drug, starting from June and July 2021, which makes patients in the UAE among the first in the world to receive this new treatment.
In addition, the National Scientific Committee and the Department of Health – Abu Dhabi have developed treatment protocols for the drug to be a reference for doctors in identifying dangerous cases, and to ensure that patients receive sotrofimab according to the level of risk and eligibility criteria.